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Abstract
Aim To assess the prospective association between objectively measured physical activity and kidney function over
4 years in people with Type 2 diabetes.
Methods Individuals (120 women and 206 men) participating in the ADDITION-Plus trial underwent assessment of
sedentary time (SED-time), time spent in moderate-to-vigorous-intensity physical activity (MVPA) and total physical
activity energy expenditure (PAEE) using a combined heart rate and movement sensor, and kidney function [estimated
glomerular filtration rate (eGFR), serum creatinine and urine albumin-to-creatinine ratio (ACR)] at baseline and after
4 years of follow-up. Multivariate regression was used to quantify the association between change in SED-time, MVPA
and PAEE and kidney measures at four-year follow-up, adjusting for change in current smoking status, waist
circumference, HbA1c, systolic blood pressure, triglycerides and medication usage.
Results Over 4 years, there was a decline in eGFR values from 87.3 to 81.7 ml/min/1.73m2 (P < 0.001); the prevalence
of reduced eGFR (eGFR < 60 ml/min/1.73m2) increased from 6.1 to 13.2% (P < 0.001). There were small increases in
serum creatinine (median: 81–84 lmol/l, P < 0.001) and urine ACR (median: 0.9–1.0 mg/mmol, P = 0.005). Increases
in SED-time were associated with increases in serum creatinine after adjustment for MVPA and cardiovascular risk
factors (b = 0.013, 95% CI: 0.001, 0.03). Conversely, increases in PAEE were associated with reductions in serum
creatinine (b = –0.001, 95% CI: –0.003, –0.0001).
Conclusion Reducing time spent sedentary and increasing overall physical activity may offer intervention opportunities
to improve kidney function among individuals with diabetes. (Trial Registry no. ISRCTN 99175498)
Diabet. Med. 00, 000 (2015)
Introduction
Diabetes is the leading cause of kidney disease [1], which is
associated with increased risk of cardiovascular events and
mortality [2]. Low levels of total physical activity energy
expenditure (PAEE) and long time spent sedentary
(SED-time) are associated with higher metabolic risk in
patients with diabetes [3]. Being physically inactive is also
associated with kidney dysfunction, in both the general
population [4–8] and among individuals with diabetes
[9,10]. However, most studies to date are cross-sectional
and rely on self-reported measures of physical activity, which
are prone to error and bias. To the best of our knowledge,
there are no studies that examine the prospective association
between objectively assessed physical activity and kidney
function among individuals with diabetes.
We aimed to assess the association between changes in
objectively measured moderate-to-vigorous-intensity physi-
cal activity (MVPA), SED-time and PAEE over 4 years with
kidney function in a cohort of individuals with recently
diagnosed Type 2 diabetes [11]. These individuals typically
have low levels of physical activity, and spend limited time in
MVPA and a large amount of time being sedentary [3,12].
Improved understanding of this relationship will inform the
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development of interventions to reduce the risk of kidney
dysfunction in this high-risk group.
Methods
ADDITION-Plus is an explanatory randomized controlled
trial, nested within the intensive treatment arm of ADDI-
TION-Cambridge study [11,13]. Eligible participants were
those aged 40–69 years who were diagnosed with Type 2
diabetes following screening in the ADDITION-Cambridge
study or clinically diagnosed during the previous 3 years. A
total of 478 eligible participants were randomly assigned to
either intensive treatment alone (n = 239) or intensive
treatment plus a facilitator-led behaviour change interven-
tion delivered at the patient’s practice (n = 239). Details of
the intervention have been described previously [11]. Because
no differences were observed in the main outcomes after
1 year, the two trial arms were pooled to conduct a cohort
analysis [3,14]. All participants provided written informed
consent. The study was approved by the Eastern Multi-
Centre Research Ethics Committee (reference number: 02/5/
54). The trial was registered as ISRCTN99175498.
Assessment of physical activity and kidney function
Assessment of ADDITION-Plus participants included iden-
tical physiological and anthropometric measures by trained
staff following standard operating procedures at baseline, 1
and 5 years. We used data from 1 and 5 years (hereafter
referred to as baseline and follow-up) as objectively mea-
sured physical activity was only assessed at 1 and 5 years.
We measured physical activity using a combined heart rate
(HR) and movement monitor (Actiheart, CamNtech, Cam-
bridge, UK), worn continuously for at least 4 days, collecting
data in 30s resolution [15]. A graded treadmill walk test was
used to calibrate HR against known workload individually
[16]. HR data collected during the free-living period were
processed using a two-stage method of noise classification
followed by Gaussian robust regression [17]. Average
activity intensity was estimated using branched equation
modelling [18]. Resulting time-series data were summarized
into MVPA (h/day), SED-time (h/day) and PAEE (kJ/kg/day),
whilst minimizing diurnal information bias caused by non-
wear periods (segments of non-physiological data). MVPA
was defined as intensity ≥ 3.0 metabolic equivalent task
(MET) and SED-time as intensity < 1.5 MET excluding self-
reported sleep duration using a standard definition of
1 MET = 3.5 ml O2/min/kg 9 20.35 J/ml O2. For partici-
pants without the individual calibration test, data collected
during the free-living period were processed with a group
calibration equation adjusted for age, sex, b–blocker and
sleeping HR in order to translate HR into activity intensity
derived on the basis of all individuals with a treadmill test.
Self-reported habitual bedtime and wake time were evaluated
on weekdays and weekends separately using the EPIC-
Norfolk Physical Activity Questionnaire (EPAQ2) [19]. Sleep
duration was calculated as (5/7 9 weekday sleep dura-
tion) + (2/7 9 weekend sleep duration).
Urine albumin-to-creatinine ratio (ACR) was measured
with a spot urine sample. Micro-albuminuria was
defined as urine 2.5 ≤ ACR < 25 mg/mmol in men or
3.5 ≤ ACR < 25 mg/mmol in women. Macro-albuminuria
was defined as urine ACR ≥ 25 mg/mmol. Serum creatinine
was assessed using kinetic colorimetric methods. Estimated
GFR (eGFR) was calculated on the basis of age, gender and
serum creatinine using the Modification of Diet in Renal
Disease formula [20]. Decreased eGFR was defined as
eGFR < 60 ml/min/1.73m2. Chronic kidney disease (CKD)
was defined as decreased eGFR and/or albuminuria (the
presence of either micro-albuminuria or macro-albuminuria).
Covariate assessment
Standardized self-report questionnaires were used to collect
socio-economic characteristics, smoking and alcohol status.
Dietary intake was evaluated using a validated food fre-
quency questionnaire [21]. The data were subsequently
converted into total energy intake (kJ/day and kcal/day)
and fat intake (g/day).
Waist circumference was assessed halfway between the
lowest point of the costal margin and the anterior superior
iliac crest while standing. Blood pressure (BP) was assessed
after 10 min of rest using an automatic sphygmomanometer
(Omron M4; Milton Keynes, UK). Hypertension was defined
as systolic BP/diastolic BP ≥ 140/90 mmHg, with/without
anti-hypertensive treatment. HbA1c was measured in venous
samples by ion-exchange high-performance liquid chro-
matography (Tosoh Bioscience, Redditch, UK). Serum total
cholesterol, triglycerides andHDL-cholesterol were measured
using enzymatic techniques (Dimension Analyzer; Dade
Behring, Newark, NJ, USA). LDL-cholesterol was calculated
for each individual using the Friedewald equation [22].
We excluded individuals who did not have complete data
for physical activity parameters at baseline and follow-up
(n = 113), for clinical and socio-economic informa-
What’s new?
 Little is known about the prospective association
between objectively measured physical activity and
kidney function among individualswithType 2 diabetes.
 Over 4 years of follow-up, reductions in sedentary time
and increases in total physical activity energy expendi-
turewere associatedwith reductions in serum creatinine.
 Reducing time spent sedentary and increasing overall
physical activity may offer intervention opportunities
to improve kidney function among individuals with
diabetes.
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tion (n = 21), for kidney function at baseline and follow-up
(n = 14) and individuals who wore the activity monitor for
< 48 h (n = 4). The present analyses therefore included 326
participants.
Statistical analysis
To compare the differences between baseline and follow-up,
paired t-tests or Wilcoxon signed rank tests were used for
continuous data, and McNemar’s test was used for categor-
ical variables. We also compared baseline socio-economic
and clinical characteristics between included individuals
(n = 326) and those excluded (n = 152).
Multivariate linear regression analysis was used to exam-
ine the association between changes (Δ) in MVPA, SED-time
and PAEE (defined as follow-up values minus baseline
values) with eGFR, serum creatinine and urine ACR at
follow-up. Serum creatinine and urine ACR were log-
transformed in order to meet the assumption of linear
regression. Model 1 was adjusted for baseline age, sex, socio-
economic status, baseline MVPA (when the exposure was
ΔMVPA), baseline SED-time (when the exposure was ΔSED-
time), baseline PAEE (when the exposure was ΔPAEE),
baseline eGFR (when the outcome was eGFR at follow-up),
baseline serum creatinine (when the outcome was serum
creatinine at follow-up), and baseline urine ACR (when the
outcome was urine ACR at follow-up). Model 2 was further
adjusted for baseline and ΔSED-time (when ΔMVPA was the
exposure) or baseline and ΔMVPA (when ΔSED-time was the
exposure). Model 3 was further adjusted for changes in
cardiovascular risk factors, namely current smoking status,
waist circumference, systolic BP, HbA1c, serum triglycerides
and medication usage, including glucose-lowering, lipid-
lowering, anti-hypertensive and aspirin medication. Linear-
ity, normality, homoscedasticity and absence of multi-
collinearity were checked for all models. In a secondary
analysis we used multivariable logistic regression to explore
the associations between changes in SED-time, MVPA and
PAEE between baseline and follow-up with the dichotomous
outcome of CKD at follow-up adjusting for the same
variables above and the additional adjustment of baseline
CKD status. Statistical analyses were performed using Stata/
SE 12.0 (Stata-Corp, College Station, TX, USA). Statistical
significance was set at P < 0.05.
Results
Among the participants included in this analysis (n = 326),
the mean (standard deviation [SD]) age was 61.2 (7.1) years.
Median duration of diabetes was 1.4 years (interquartile
range [IQR]: 1.12.9). The majority were male (63%) and
from a managerial/professional socio-economic class (43%).
Compared to those included, excluded participants (n = 152)
reported shorter sleep duration and had longer sedentary and
shorter MVPA time at baseline. There was no difference in
kidney function or other baseline characteristics between
included and excluded participants (data not shown).
After 4 years of follow-up, participants reported lower
total energy intake and longer sleep duration at follow-up
compared with baseline (Table 1). There was a small
increase in BMI for men. Mean HbA1c levels increased from
49 to 53 mmol/mol (6.6 to 7.0%), while diastolic BP, total
cholesterol and LDL-cholesterol levels declined. The preva-
lence of hypertension increased from 77.3 to 84.7%. There
was a small but significant increase in HDL-cholesterol in the
whole cohort. The proportion of participants prescribed
glucose-lowering, lipid-lowering and anti-hypertensive
medication increased significantly during the follow-up
period.
There was a decline in eGFR values from 87.3 to 81.7 ml/
min/1.73m2 (P < 0.001); the prevalence of decreased eGFR
increased from 6.1 to 13.2% (P < 0.001). There were small
increases in urine ACR from a median of 0.9 to 1.0 mg/mmol
(P = 0.005) and serum creatinine from a median of 81 to
84 lmol/l (P < 0.001). There was no significant increase in
the proportion of participants with micro- or macro-albu-
minuria. The prevalence of CKD was 19.0% at baseline and
27.3% at follow-up (P = 0.001).
In terms of objectively measured health behaviours, PAEE
levels declined from 33.7 to 28.7 kJ/kg/day (P < 0.001),
whereas SED-time increased over the 4–year follow-up (10.5
vs. 11.1, P < 0.001). Time spent in MVPA was similar at
baseline and follow-up for women, whereas men showed a
significant reduction in MVPA (median: 0.59 to 0.49 h/day,
P = 0.005).
There was a significant inverse association between change
in SED-time and eGFR at follow-up in Model 1 (Table 2).
However, after adjustment forMVPA and cardiovascular risk
factors (Models 2 and 3), these associations were attenuated.
By contrast, change in PAEE was positively associated with
eGFR at follow-up inModel 1. This associationwas no longer
significant after further adjustment of cardiovascular risk
factors (Model 3). There was no significant association
between changes in MVPA and eGFR at follow-up in any of
the models. There was a positive association between change
in SED-time and serum creatinine at follow-up in all adjusted
models, e.g. on average, participants who increased their SED-
time between baseline and follow-up had increased levels of
creatinine at follow-up. Conversely, increased PAEE was
inversely associated with serum creatinine at follow-up in all
adjustedmodels. Therewas no association between changes in
MVPA and creatinine. There were no significant associations
between change in SED-time, MVPA or PAEE and urine ACR
at follow-up.
When examining kidney dysfunction as a binary outcome
at 4–year follow-up, there was no association between
change in MVPA or change in SED-time with CKD in fully
adjusted models (Table 3). An increase in PAEE was
significantly associated with a reduction in the relative risk
of developing CKD in all models (Model 3: relative risk:
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0.964, 95% CI: 0.936–0.993, P = 0.014, for every 1 kJ/kg/
day difference in PAEE change).
Discussion
Among a cohort of individuals with recently diagnosed
diabetes, increases in sedentary time over 4 years were
associated with increases in serum creatinine after adjust-
ment for time spent in moderate-to-vigorous-intensity phys-
ical activity and cardiovascular risk factors. Conversely,
increases in total physical activity energy expenditure were
associated with reductions in serum creatinine and with a
lower risk of developing CKD.
Previous research on the association between physical
activity and kidney function comes primarily from the general
population. The National Health and Nutrition Examination
Table 1 Characteristics of the ADDITION-Plus cohort at baseline and follow-up (n = 326)
Characteristic Baseline Follow-up P
Demographic and lifestyle factors
Age (years) 61.2 (7.1)  
Male sex (%) 63.2  
Occupational socio-economic class (%)  
Managerial and professional 42.9
Intermediate 24.5
Routine and manual 32.5
Alcohol consumption (g/day)a 3.8 (0.1, 10) 2.0 (0, 10.0) 0.213
Current smoker (%) 12.0 11.7 1.000
Fat intake (g/day) 59.5 (20.8) 60.5 (25.9) 0.429
Total energy intake (kJ/day)a 7162.3 (6044.4, 8451.1) 6644.0 (5686.4, 8094.4) 0.009
Total energy intake (kcal/day)a 1698.9 (1431.5, 2001.7) 1579.5 (1347.0, 1917.8) 0.010
Average sleep duration (h/day)b 8.2 (1.1) 8.4 (1.0) < 0.001
Clinical/biochemical measures
BMI (kg/m2)
Female 32.2 (5.5) 32.3 (5.7) 0.510
Male 31.3 (4.9) 31.6 (5.4) 0.015
Waist circumference (cm)
Female 103.7 (12.6) 102.5 (12.8) 0.063
Male 110.5 (12.6) 110.5 (13.2) 0.961
Obesity (%) 57.7 58.3 0.883
HbA1c [mmol/mol, (%)] 49 (10) [6.6 (0.9)] 53 (10) [7.0 (0.9)] < 0.001
Hypertension (%) 77.3 84.7 < 0.001
Systolic BP (mmHg) 130.0 (17.7) 131.8 (16.6) 0.054
Diastolic BP (mmHg) 76.0 (9.1) 73.3 (9.2) < 0.001
Total cholesterol (mmol/l) 4.3 (0.9) 4.1 (0.9) 0.013
Triglycerides (mmol/l)a 1.6 (1.1, 2.2) 1.6 (1.2, 2.3) 0.359
HDL-cholesterol (mmol/l) 1.2 (0.3) 1.3 (0.3) < 0.001
LDL-cholesterol (mmol/l) 2.3 (0.7) 2.1 (0.7) < 0.001
Kidney measures
eGFR (ml/min/1.73m2) 87.3 (29.2) 81.3 (23.3) < 0.001
Decreased eGFR (%) 6.1 13.2 < 0.001
Urine ACR (mg/mmol)a 0.9 (0.5, 1.8) 1.0 (0.6, 2.1) 0.005
Micro-albuminuria (%) 13.8 16.9 0.184
Macro-albuminuria (%) 1.5 2.5 0.453
Serum creatinine (lmol/l)a 81 (69, 91) 84 (72, 93) < 0.001
CKD (%) 19.0 27.3 0.001
Prescribed medication
Glucose-lowering medication (%) 48.9 71.2 < 0.001
Lipid-lowering medication (%) 77.6 85.3 0.003
Anti-hypertensive medication (%) 73.5 78.8 < 0.001
Aspirin (%) 56.4 56.4 1.000
Objectively measured health behaviours
PAEE (kJ/kg/day) 33.7 (17.0) 28.7 (15.3) < 0.001
Duration SED-time (h/day) 10.5 (2.5) 11.1 (2.1) < 0.001
Duration MVPA (h/day)a
Female 0.23 (0.09, 0.61) 0.18 (0.04, 0.50) 0.191
Male 0.59 (0.27, 1.23) 0.49 (0.17, 1.03) 0.005
All data are means (SD) or percentage unless otherwise indicated.
aMedian (IQR).
bSleep duration was calculated using the self-reported EPIC-Norfolk Physical Activity Questionnaire (EPAQ2).
Obesity was defined as BMI > 30 kg/m2. Hypertension was defined as systolic BP/diastolic BP ≥ 140/90 mmHg, with or without anti-
hypertension treatment.
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Survey (NHANES) II showed that self-reported inactive
individuals had a higher risk of CKD-related deaths and
end-stage renal disease compared with active individuals [6].
In a Norwegian population without signs of CKD at baseline,
high levels of self-reported physical activity at baseline were
associated with increases in eGFR only in women after 7 years
of follow-up [4]. However, a report from the Australian
Diabetes, Obesity and Lifestyle Study (AusDiab) of 5853
participants who were free of CKD at baseline found no
significant association between self-reported physical activity
and CKD incidence after 5 years of follow-up [8]. We were
also unable to demonstrate any significant association
between change in objectively measured time spent in mod-
erate-to-vigorous-intensity physical activity or total energy
expenditure and eGFR at 4–year follow-up. In terms of
sedentary time and kidney function, the AusDiab study
showed that television-viewing time was a risk factor for low
eGFR in men over 5 years of follow-up [5], although the
association between physical activity and eGFR varied across
previous studies. Overall, these studies suggest a protective
role of physical activity on kidney function.
One cross-sectional study in 3587 women without diabetes
found an inverse association between self-reported time spent
walking and strenuous activity with albuminuria [7]. How-
ever, the AusDiab study of 5978 participants at risk of
albuminuria showed that self-reported physical activity was
not associated with long-term albuminuria [8]. In patients
with Type 2 diabetes, one small intervention study with 30
male participants, who underwent regular aerobic exercise
for 6 months, showed reduced urine ACR after 6 months
follow-up [10]. In this analysis, there was no evidence of an
association between any physical activity measures and ACR.
Only one small study of 17 patients with CKD has focused
on the effect of exercise on serum creatinine level [23].
Participants undergoing water-based exercise showed
reduced serum creatinine during a period of 12 weeks. In
our study, sedentary time and total energy expenditure were
associated with serum creatinine levels.
Our results are not fully consistent with previous studies.
One possible explanation might be the different method for
assessing physical activity. Most of the reports used ques-
tionnaires to collect the frequency, duration and intensity of
physical activity [4–10]. Information on physical activity
derived from self-reported questionnaires is subject to error
and social desirability bias or cognitive limitations due to
recall or comprehension [24]. A second possible reason might
be the different study populations. Most studies focused on
the general population [4–8] and only a few studies were
conducted among individuals with diabetes [9,10]. Our
cohort focused on patients in the first 5 years after diagnosis
of diabetes. If we had followed our cohort for longer, we may
have discovered stronger relationships between physical
Table 2 Association between change in MVPA, SED-time and PAEE from baseline to four-year follow-up and kidney function at 4 years in the
ADDITION-Plus trial cohort
Exposure
eGFR at follow-up log (Serum creatinine) at follow-up log (Urine ACR) at follow-up
b (95% CI) P b (95% CI) P b (95% CI) P
Model 1 DSED-time –0.984 (–1.893, –0.076) 0.034 0.012 (0.003, 0.022) 0.012 –0.030 (–0.090, 0.029) 0.314
DMVPA 2.204 (–0.419, 4.827) 0.099 –0.020 (–0.048, 0.008) 0.166 –0.024 (–0.195, 0.146) 0.779
DPAEE 0.153 (0.018, 0.288) 0.026 –0.002 (–0.003, –0.0002) 0.025 0.002 (–0.007, 0.008) 0.706
Model 2 DSED-time –0.773 (–1.861, 0.316) 0.163 0.012 (0.0003, 0.024) 0.045 –0.049 (–0.120, 0.022) 0.179
DMVPA 1.012 (–2.121, 4.145) 0.525 –0.001 (–0.035, 0.033) 0.954 –0.101 (–0.305, 0.102) 0.327
Model 3 DSED-time –0.791 (–1.894, 0.313) 0.159 0.013 (0.001, 0.025) 0.030 –0.048 (–0.120, 0.023) 0.187
DMVPA 0.475 (–2.694, 3.643) 0.768 0.008 (–0.026, 0.043) 0.652 –0.119 (–0.304, 0.066) 0.171
DPAEE 0.128 (–0.009, 0.266) 0.067 –0.001 (–0.003, –0.0001) 0.048 –0.001 (–0.009, 0.009) 0.977
Model 1 was adjusted for age, sex, socio-economic status, baseline value of the relevant outcome, and baseline value of the relevant exposure.
Model 2 was further adjusted for baseline SED-time and DSED-time (when DMVPA was the exposure) or baseline MVPA and DMVPA
(when DSED-time was the exposure).
Model 3 was further adjusted for Dcurrent smoking status, Dwaist, DHbA1c, Dsystolic BP, Dtriglycerides, Dglucose-lowering drugs, Dlipid-
lowering drugs, Danti-hypertensive drugs and Daspirin from baseline to 4 years.
Table 3 Multivariable logistic regression analysis of the association
between change in MVPA, SED-time and PAEE from baseline to 4–
year follow-up and CKD at four years in the ADDITION-Plus trial
cohort
Relative risk 95% CI P
Model 1 DSED-time 1.149 0.968–1.364 0.113
DMVPA 0.544 0.294–1.007 0.053
DPAEE 0.968 0.941–0.995 0.023
Model 2 DSED-time 1.095 0.887–1.352 0.397
DMVPA 0.689 0.333–1.428 0.316
Model 3 DSED-time 1.088 0.867–1.365 0.466
DMVPA 0.591 0.272–1.282 0.183
DPAEE 0.964 0.936–0.993 0.014
Model 1 was adjusted for age, sex, socio-economic status,
baseline CKD status and baseline value of the relevant
exposure.
Model 2 was further adjusted for baseline SED-time and DSED-
time (when DMVPA was the exposure) or baseline MVPA and
DMVPA (when DSED-time was the exposure).
Model 3 was further adjusted for Dcurrent smoking status,
Dwaist, DHbA1c, Dsystolic BP, Dtriglycerides, Dglucose-lower-
ing drugs, Dlipid-lowering drugs, Danti-hypertensive drugs and
Daspirin from baseline to 4 years.
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activity and kidney function. Finally, people with recently
diagnosed diabetes spend significant amounts of time in
sedentary behaviours with limited time spent in moderate-to-
vigorous-intensity physical activity [3]. Thus, we observed
the strongest associations between sedentary time and total
energy expenditure with kidney function. The lack of
association between time spent in moderate-to-vigorous-
intensity physical activity and outcome may, therefore, be
explained by low and homogenous levels of physical activity
in the study population.
The strengths of our study include the prospective design,
and validated methods to assess exposure, outcomes and
covariates. We measured physical activity objectively using a
combined HR and movement sensor, which allowed us to
discriminate between time spent in different intensities of
physical activity. This is crucial to accurately estimate
sedentary time in recently diagnosed Type 2 diabetes
patients, who spend a considerable amount of time in
sedentary behaviours. Furthermore, the device used in this
study has been demonstrated a reliable and valid tool [15],
and the use of branched equation modelling improves the
precision of estimates of intensity as well as total energy
expenditure [18,25]. We also focused on individuals with
recently diagnosed Type 2 diabetes. Because diabetes dura-
tion is a key contributor to kidney dysfunction [26], our
study may provide intervention points for preventing or
slowing the progression of kidney dysfunction.
Several limitations should also be addressed. First, urine
ACR was measured only once at each time point using
random spot urine sample. Potential bias may be present in
patients with high protein excretion when estimating urine
ACR [27], which might attenuate the associations between
physical activity and urine ACR. Second, we did not consider
time spent napping during the day, which might lead to
misclassification of sleep time as sedentary time and vice
versa. Also, participants may misreport sleep duration. A
more precise measure of sleep duration, such as polysomnog-
raphy recording biophysiological changes during sleep, might
reduce this bias, but is unlikely to be carried out among free-
living participants in large-scale epidemiological cohorts.
Third, although we adjusted for conventional risk factors for
kidney dysfunction, we cannot rule out other possible
confounders or unmeasured factors such as changes in lean
mass and dietary intake of creatinine. Conversely, the
adjustment of cardiovascular risk factors may have attenu-
ated the association between physical activity measures and
kidney function. Fourth, this was a post-hoc question and we
carried out a number of statistical tests on multiple exposure-
outcome relationships, which may have led to spurious
positive results. Finally, our study was conducted in a
relatively homogeneous sample with the same ethnic back-
ground; our results may therefore not be generalizable to
other populations.
Being physically active reduces cardiovascular disease and
total mortality in patients with Type 2 diabetes [28], and
early intervention targeted at increasing physical activity
may be an effective strategy to reduce the risk of later
macrovascular complications. We previously showed that
objectively measured sedentary time was associated with
metabolic risk factors independent of time spent in moder-
ate-to-vigorous-intensity physical activity [3]. Focusing on
reducing sedentary behaviour and/or increasing total phys-
ical activity energy expenditure, rather than solely targeting
increasing the time spent on physical activity, might be a
more effective paradigm to improve health outcomes. This is
particularly important because patients with Type 2 diabetes
spend a long time sitting and less time being physically
active. Our findings suggest that increasing total physical
activity energy expenditure, regardless of activity intensity,
has beneficial effect on kidney function. Our data also
suggest that apart from the World Health Organization
guidelines of spending at least 150 min on moderate-to-
vigorous-intensity physical activity per week, interventions
that increase total physical activity energy expenditure by
reducing sedentary time may also benefit patients. For
example, an increase of 6 kJ/kg/day energy expenditure,
which may be achieved by shifting 1 h of time spent being
sedentary to light physical activity, would reduce the risk of
kidney dysfunction by 20%.
In conclusion, among a cohort of individuals with recently
diagnosed diabetes, we observed that increases in sedentary
time over 4 years were associated with increases in serum
creatinine, while increases in total physical activity energy
expenditure were associated with reductions in serum crea-
tinine and a lower risk of CKD. Encouraging patients with
Type 2 diabetes to increase their overall physical activity and
decrease sedentary time may have beneficial effects on kidney
function.
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